WuXi XDC Cayman, Inc. (HK:2268)
:2268
Want to see HK:2268 full AI Analyst Report?
2268 Stock Chart & Stats
HK$54.80
HK$1.55(5.24%)
At close: 4:00 PM EST
HK$54.80
HK$1.55(5.24%)
Day’s Range― - ―
52-Week RangeHK$38.80 - HK$85.50
Previous CloseN/A
Volume4.11M
Average Volume (3M)6.66M
Market Cap
HK$63.22B
Enterprise ValueHK$59.13B
Total Cash (Recent Filing)HK$7.47B
Total Debt (Recent Filing)HK$879.52M
Price to Earnings (P/E)39.0
Beta1.11
Next Earnings
Aug 25, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding1,260,609,400
10 Day Avg. Volume10,688,598
30 Day Avg. Volume6,656,062
Financial Highlights & Ratios
PEG Ratio1.31
Price to Book (P/B)6.72
Price to Sales (P/S)12.13
P/FCF Ratio113.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$81.58Price Target Upside48.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.63
Revenue Forecast (FY)HK$8.14B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high operating and net margins indicate strong pricing power and efficient execution in ADC development and manufacturing. Durable margins support reinvestment into capacity and R&D, provide a buffer against demand swings, and underpin long-term cash generation potential.
Solid Top-line GrowthConsistent revenue expansion reflects growing client demand for outsourced ADC capabilities and successful scaling of services. Persistent top-line growth helps spread fixed costs, enables margin expansion over time, and increases the scope for long-term market share gains in the ADC CDMO market.
Conservative Balance SheetVery low leverage and strong equity relative to assets reduce financial risk and increase strategic flexibility. This balance sheet strength supports funding for capex, capacity expansion or strategic deals without heavy reliance on external financing, improving resilience across cycles.
Bears Say
Volatile Cash ConversionFree cash flow has been inconsistent despite strong accounting profits, signalling variability in working capital and capex timing tied to project cycles. Weak cash conversion reduces the company's ability to self-fund expansion or buffer downturns and may force periodic external financing.
Margin CompressionSequential margin decline suggests rising cost intensity, competitive pressure or mix shifts toward lower-margin work as the company scales. If persistent, margin pressure can erode the firm's profitability advantage and constrain long-term free cash flow and investment capacity.
Concentration In ADC NicheA specialized ADC-only CDMO model drives expertise and premium pricing but concentrates revenue exposure to ADC program pipelines and biotech/pharma outsourcing trends. Slower ADC adoption, client cancellations or loss of major programs would disproportionately impact revenues.
WuXi XDC Cayman, Inc. News
2268 FAQ
What was WuXi XDC Cayman, Inc.’s price range in the past 12 months?
WuXi XDC Cayman, Inc. lowest stock price was HK$38.80 and its highest was HK$85.50 in the past 12 months.
What is WuXi XDC Cayman, Inc.’s market cap?
WuXi XDC Cayman, Inc.’s market cap is HK$63.22B.
When is WuXi XDC Cayman, Inc.’s upcoming earnings report date?
WuXi XDC Cayman, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 79 days.
How were WuXi XDC Cayman, Inc.’s earnings last quarter?
WuXi XDC Cayman, Inc. released its earnings results on Mar 23, 2026. The company reported HK$0.699 earnings per share for the quarter, missing the consensus estimate of HK$0.711 by -HK$0.011.
Is WuXi XDC Cayman, Inc. overvalued?
According to Wall Street analysts WuXi XDC Cayman, Inc.’s price is currently Undervalued.
Does WuXi XDC Cayman, Inc. pay dividends?
WuXi XDC Cayman, Inc. does not currently pay dividends.
What is WuXi XDC Cayman, Inc.’s EPS estimate?
WuXi XDC Cayman, Inc.’s EPS estimate is 0.89.
How many shares outstanding does WuXi XDC Cayman, Inc. have?
WuXi XDC Cayman, Inc. has 1,260,609,400 shares outstanding.
What happened to WuXi XDC Cayman, Inc.’s price movement after its last earnings report?
WuXi XDC Cayman, Inc. reported an EPS of HK$0.699 in its last earnings report, missing expectations of HK$0.711. Following the earnings report the stock price went down -4.06%.
Which hedge fund is a major shareholder of WuXi XDC Cayman, Inc.?
Currently, no hedge funds are holding shares in HK:2268
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi XDC Cayman, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.79%
12-Months-Change
Fundamentals
Return on Equity
16.29%
Trailing 12-Months
Asset Growth
65.58%
Trailing 12-Months
Company Description
WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
2268 Stock 12 Month Forecast
Average Price Target
HK$81.58
▲(48.87% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---